SG11201401175SA - Treatment protocol of diabetes type 2 - Google Patents
Treatment protocol of diabetes type 2Info
- Publication number
- SG11201401175SA SG11201401175SA SG11201401175SA SG11201401175SA SG11201401175SA SG 11201401175S A SG11201401175S A SG 11201401175SA SG 11201401175S A SG11201401175S A SG 11201401175SA SG 11201401175S A SG11201401175S A SG 11201401175SA SG 11201401175S A SG11201401175S A SG 11201401175SA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment protocol
- diabetes type
- diabetes
- type
- protocol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11187169 | 2011-10-28 | ||
| PCT/EP2012/071271 WO2013060850A1 (en) | 2011-10-28 | 2012-10-26 | Treatment protocol of diabetes type 2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201401175SA true SG11201401175SA (en) | 2014-09-26 |
Family
ID=47071308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201401175SA SG11201401175SA (en) | 2011-10-28 | 2012-10-26 | Treatment protocol of diabetes type 2 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20130296236A1 (en) |
| EP (1) | EP2771024B1 (en) |
| JP (1) | JP6329487B2 (en) |
| KR (1) | KR101967941B1 (en) |
| CN (2) | CN104066441A (en) |
| AU (1) | AU2012328388B2 (en) |
| BR (1) | BR112014010200A2 (en) |
| CA (1) | CA2851690C (en) |
| HK (1) | HK1198577A1 (en) |
| IL (1) | IL232251B (en) |
| IN (1) | IN2014CN02616A (en) |
| MX (1) | MX359329B (en) |
| MY (1) | MY170713A (en) |
| RU (1) | RU2014121386A (en) |
| SG (1) | SG11201401175SA (en) |
| WO (1) | WO2013060850A1 (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20170369A (en) | 2008-10-17 | 2017-11-01 | Sanofi Aventis Deutschland | COMBINATION OF AN INSULIN AND A GLP-1 AGONIST (Divisional 2011-0188) |
| US20110118178A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
| EP3417871B1 (en) | 2009-11-13 | 2020-12-23 | Sanofi-Aventis Deutschland GmbH | Pharmaceutical composition comprising a glp-1-agonist, an insulin, and methionine |
| EP3345593B1 (en) | 2009-11-13 | 2023-09-06 | Sanofi-Aventis Deutschland GmbH | Pharmaceutical composition comprising despro36exendin-4(1-39)-lys6-nh2 and methionine |
| KR101823320B1 (en) | 2010-08-30 | 2018-01-31 | 사노피-아벤티스 도이칠란트 게엠베하 | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| WO2013030160A1 (en) | 2011-08-29 | 2013-03-07 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
| AR087744A1 (en) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE |
| UA116217C2 (en) | 2012-10-09 | 2018-02-26 | Санофі | Exendin-4 derivatives as dual glp1/glucagon agonists |
| WO2014096149A1 (en) | 2012-12-21 | 2014-06-26 | Sanofi | Exendin-4 Derivatives |
| TWI641381B (en) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| US20160038077A1 (en) * | 2013-06-27 | 2016-02-11 | Inspark Technologies, Inc. | Systems, Devices, and/or Methods for Identifying Time Periods of Insufficient Blood Glucose Testing |
| TW201609795A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | EXENDIN-4 peptide analogues as dual GLP-1/GIP receptor agonists |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| JP6735674B2 (en) | 2014-01-09 | 2020-08-05 | サノフイＳａｎｏｆｉ | Stabilized pharmaceutical formulation of insulin aspart |
| WO2015104311A1 (en) | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| JP6641280B2 (en) | 2014-01-09 | 2020-02-05 | サノフイＳａｎｏｆｉ | Stabilized pharmaceutical formulations of insulin analogues and / or insulin derivatives |
| TW201625669A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4 |
| TW201625670A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4 |
| TW201625668A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| ES2949095T3 (en) | 2014-12-12 | 2023-09-25 | Sanofi Aventis Deutschland | Insulin glargine/lixisenatide fixed ratio formulation |
| TWI706779B (en) * | 2015-01-16 | 2020-10-11 | 德商賽諾菲阿凡提斯德意志有限公司 | Treatment of pediatric type 2 diabetes mellitus patients |
| TWI748945B (en) * | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | Treatment type 2 diabetes mellitus patients |
| TW201705975A (en) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | Treatment of type 2 diabetes mellitus patients |
| AR105319A1 (en) | 2015-06-05 | 2017-09-27 | Sanofi Sa | PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR |
| TW201706291A (en) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| EP1663200A2 (en) * | 2003-09-02 | 2006-06-07 | Prosidion Limited | Combination therapy for glycaemic control |
| EP2248531A1 (en) * | 2004-08-03 | 2010-11-10 | Emisphere Technologies, Inc. | Antidiabetic oral insulin-biguanide combination |
| DK2393412T3 (en) * | 2009-02-04 | 2017-12-11 | Sanofi Aventis Deutschland | MEDICAL DEVICE AND PROCEDURE FOR PROVIDING Glycemic Control Information |
| JP5980466B2 (en) * | 2009-11-13 | 2016-08-31 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Method for treating type 2 diabetes including addition therapy to insulin glargine and metformin |
| EP2329848B2 (en) * | 2009-11-13 | 2019-06-19 | Sanofi-Aventis Deutschland GmbH | Lixisenatide as add-on therapy to insulin glargine and metformin for treating type 2 diabetes |
| KR20110052990A (en) * | 2009-11-13 | 2011-05-19 | 사노피-아벤티스 도이칠란트 게엠베하 | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
| US20110118178A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
| US9821032B2 (en) * | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
-
2012
- 2012-10-26 MX MX2014005139A patent/MX359329B/en active IP Right Grant
- 2012-10-26 BR BR112014010200-7A patent/BR112014010200A2/en not_active Application Discontinuation
- 2012-10-26 CA CA2851690A patent/CA2851690C/en active Active
- 2012-10-26 AU AU2012328388A patent/AU2012328388B2/en active Active
- 2012-10-26 KR KR1020147011152A patent/KR101967941B1/en active IP Right Grant
- 2012-10-26 MY MYPI2014000971A patent/MY170713A/en unknown
- 2012-10-26 SG SG11201401175SA patent/SG11201401175SA/en unknown
- 2012-10-26 EP EP12775720.1A patent/EP2771024B1/en active Active
- 2012-10-26 CN CN201280065132.1A patent/CN104066441A/en active Pending
- 2012-10-26 IN IN2616CHN2014 patent/IN2014CN02616A/en unknown
- 2012-10-26 RU RU2014121386/15A patent/RU2014121386A/en unknown
- 2012-10-26 CN CN201711071123.4A patent/CN107693783A/en active Pending
- 2012-10-26 JP JP2014537630A patent/JP6329487B2/en active Active
- 2012-10-26 WO PCT/EP2012/071271 patent/WO2013060850A1/en active Application Filing
- 2012-10-26 US US13/661,476 patent/US20130296236A1/en not_active Abandoned
-
2014
- 2014-04-24 IL IL23225114A patent/IL232251B/en active IP Right Grant
- 2014-12-01 HK HK14112062A patent/HK1198577A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20130296236A1 (en) | 2013-11-07 |
| WO2013060850A1 (en) | 2013-05-02 |
| IN2014CN02616A (en) | 2015-06-26 |
| KR101967941B1 (en) | 2019-04-10 |
| IL232251B (en) | 2019-10-31 |
| MY170713A (en) | 2019-08-27 |
| RU2014121386A (en) | 2015-12-10 |
| JP6329487B2 (en) | 2018-05-23 |
| CN104066441A (en) | 2014-09-24 |
| CA2851690C (en) | 2022-07-26 |
| KR20140093935A (en) | 2014-07-29 |
| CA2851690A1 (en) | 2013-05-02 |
| AU2012328388B2 (en) | 2017-06-15 |
| IL232251A0 (en) | 2014-06-30 |
| EP2771024A1 (en) | 2014-09-03 |
| MX2014005139A (en) | 2014-08-27 |
| BR112014010200A2 (en) | 2020-10-27 |
| HK1198577A1 (en) | 2015-04-30 |
| CN107693783A (en) | 2018-02-16 |
| AU2012328388A1 (en) | 2014-05-15 |
| EP2771024B1 (en) | 2018-11-28 |
| JP2015501314A (en) | 2015-01-15 |
| MX359329B (en) | 2018-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1198577A1 (en) | Treatment protocol of diabetes type 2 | |
| ZA201403795B (en) | Formulations for the treatment of diabetes | |
| EP2723384A4 (en) | Treatment of proteinopathies | |
| IL223289A0 (en) | Treatment of type 2 diabetes | |
| IL225896A0 (en) | Treatment of mecp2-associated disorders | |
| HK1202819A1 (en) | Treatment of type i and type ii diabetes i ii | |
| ZA201308117B (en) | Avian-based treatment | |
| GB201107467D0 (en) | Novel treatment of pain | |
| HK1196953A1 (en) | Formulations for the treatment of diabetes | |
| GB201121044D0 (en) | Treatment of solutions | |
| AU2011902407A0 (en) | Treatment of pain | |
| GB201111247D0 (en) | Treatment | |
| GB201109119D0 (en) | Treatment | |
| GB201102271D0 (en) | Treatment | |
| GB201102269D0 (en) | Treatment | |
| GB201102282D0 (en) | Treatment | |
| GB201102263D0 (en) | Treatment | |
| GB201102284D0 (en) | Treatment | |
| GB201102288D0 (en) | Treatment | |
| GB201102276D0 (en) | Treatment | |
| GB201102265D0 (en) | Treatment | |
| GB201102272D0 (en) | Treatment | |
| GB201102273D0 (en) | Treatment | |
| GB201102270D0 (en) | Treatment | |
| GB201102277D0 (en) | Treatment |